Study of Oxaliplatin Combined with 5-fluorouracil and Folinic Acid ( FOLFOX 4 regimen) as Second Line Treatment for the Patients with Advanced Gastric Cancer

Objective 　To evaluate the effect and toxicity of oxaliplatin combined with 5-fluorouracil and folinic acid ( FOLFOX4 regimen) as second-line treatment for the patient s with advanced gastric cancer (AGC) . Methods 　34 cases with advanced gastric cancer and received Taxane regimen chemotherapy before, were t reated with FOLFOX4 regimen. Results 　33 patients were evaluated for clinical response. The overall response rate was 21. 2 % (CR 1, PR 6, SD 14 and PD 12) . The median duration of response was 5 months. Median TTP was 4. 2 months. Median survival time was 6 months. 34 patient s were evaluated for toxicity. The major reaction was bone suppression, nausea/ vomiting and peripheral nerve toxicity. Conclusion 　The FOL FOX4 regimen is an active and good regimen as the second line treatment for AGC, with favorable toxicity profile and deserves further evaluation in randomized studies.